SPARK THERAPEUTICS

We understand that living with a genetic disease can be challenging for patients and their caregivers. Your determination-and the determination of others like you-motivates the work that we do. Here at Spark® Therapeutics, we take a patient-centric approach to our research and support services... For patients with a genetically diagnosed inherited retinal disease due to mutations in both copies of the RPE65 who are eligible for treatment with LUXTURNA® (voretigene neparvovec-rzyl), Spark Therapeutics Generation Patient Services provides the ongoing support, financial information, and outreach resources you need most.

Also known as: Spark Therapeutics, Inc.